EyRis

What EyRis does

EyRIS Pte Ltd is a Singapore-based private health technology company that develops and commercializes deep learning systems for automated screening of retinal and other chronic diseases. Founded in 2017, the company operates from Singapore and is led by Founding CEO Lai Teik Kin, with co-founders including Prof Wong Tien Yin (Singapore National Eye Centre / Duke-NUS) and Dr Daniel Ting (SNEC / Duke-NUS), alongside NUS School of Computing computer science professors who co-invented the core technology. The company was built on a foundation of clinical research collaborations with the Singapore Eye Research Institute (SERI) and Singapore National Eye Centre (SNEC).

The flagship product is SELENA+, a proprietary Deep Learning System built on convolutional neural network architecture that analyzes retinal fundus photographs to automatically detect three conditions from a single image: referable diabetic retinopathy, possible glaucoma suspect, and age-related macular degeneration. The system was trained on what the company describes as the world's first and largest dataset of nearly 500,000 retinal images, validated across 10 external datasets from multi-ethnic populations. The technology has been peer-reviewed, including publication in THE LANCET, and is supported by ISO 13485 certification and EU MDR compliance. EyRIS has expanded its product line to include SIVA (smartphone-based retinal vessel analysis) and a chronic kidney disease detection algorithm, with active exploration of Alzheimer's-related AI applications through a strategic alliance with I-Cognitio Sciences.

The business model centers on enterprise B2B sales to government health ministries and hospital systems for population-scale diabetic retinopathy screening programs, supplemented by channel partners and OEM integrations. Flagship national deployments include the Sultanate of Oman Ministry of Health and Brunei Darussalam Ministry of Health, alongside Singapore's Integrated Diabetic Retinopathy Programme (SIDRP) which screens 120,000+ patients annually across 30+ sites. Distribution is augmented through regional partners (Al-Dawaa in KSA, Advance Innovation in Myanmar) and technology integrations with Topcon Healthcare's Harmony RS platform across 18 Asian countries, Optomed, and other ophthalmic device manufacturers. Regulatory clearances span Singapore, EU (MDR), Australia (TGA), UAE, Thailand, Indonesia, and Brazil. The company employs 11-50 people and serves customers in 20+ countries across Asia Pacific, the Middle East, Africa, Latin America, and North America.

Name

EyRis

Legal name

EyRIS Pte Ltd

Website

https://eyris.io

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

EyRIS Pte Ltd is a Singapore-based AI healthcare company that develops SELENA+, a deep learning system for automated detection of diabetic retinopathy, glaucoma, and macular degeneration from retinal images. It serves government health ministries, hospitals, and eye care centers across more than 20 countries.

Ownership category

akta.pro rank

Product category

AI Ophthalmic Diagnostics

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB)

akta.pro secondary industry

Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN)

Keywords

• AI retinal screening
• Diabetic retinopathy detection
• Deep learning diagnostics
• Medical imaging AI
• Ophthalmology software

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Go-to-market motion3 records

Distribution channels4 records

Marketing channels3 records

Core offering

EyRIS develops and sells SELENA+, an AI Deep Learning System using Convolutional Neural Networks trained on nearly 500,000 retinal images to automatically detect diabetic retinopathy, glaucoma suspect, and age-related macular degeneration from retinal photographs. The company also offers SIVA for retinal vascular assessment and a chronic kidney disease detection algorithm, deploying these solutions to government health agencies, hospitals, and eye care centers across multiple countries.

Product overview

EyRIS operates as a single-platform AI healthcare company offering deep learning diagnostic solutions. The core product is SELENA+, an AI system for automated detection of eye diseases including diabetic retinopathy, glaucoma suspect, and age-related macular degeneration. Additionally, SIVA provides retinal vascular assessment capabilities. The company is expanding into broader diagnostic applications with a chronic kidney disease detection algorithm. EyRIS also provides tele-ophthalmology services through partnerships and deploys its AI solutions via integration with platforms like Topcon's Harmony RS.

Differentiator

Problem solved

Functional benefit

Brands

• SELENA+: AI Deep Learning System for automated detection of diabetic retinopathy, glaucoma suspect, and age-related macular degeneration from retinal images
• SIVA

Products and services

• SELENA+ AI-powered deep learning system for automated screening and detection of diabetic retinopathy, glaucoma suspect, and age-related macular degeneration from retinal fundus photographs. Uses convolutional neural networks trained on nearly 500,000 retinal images and validated across 10 external datasets from multi-ethnic populations. Designed for government health agencies, hospitals, and eye care centers conducting population-scale screening.
• SIVA (Smartphone-based Retinal Vessel Analysis) Retinal vascular assessment system that enables detailed analysis of retinal blood vessels for diagnostic purposes. Has been licensed and used by hospitals and universities in the US, Japan, China, Australia and other countries. Designed for clinical and research institutions conducting retinal vascular analysis.
• Chronic Kidney Disease Detection Algorithm Deep learning algorithm extending EyRIS's AI diagnostic capabilities beyond ophthalmology to detect chronic kidney disease, demonstrating the company's expansion into broader healthcare diagnostics. Designed for healthcare providers and screening programs.

Quantifiable outcome

• 120,000+ patients screened annually through Singapore national program
• +2 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature3 records

Partnerships

Twelve partnerships are on record, tiered flagship, major, core and minor.

• Sultanate of Oman Ministry of HealthflagshipStrategic or Co-development Partner · 13 August 2025National program partnership for diabetic retinopathy screening powered by EyRIS AI technology covering the entire Oman population.
• Al-Dawaa Medical Services (KSA)majorChannel Partner/ Reseller/ Distributor · 21 October 2024MOU signed for distribution and deployment of EyRIS AI solutions in the Kingdom of Saudi Arabia.
• Brunei Darussalam Ministry of HealthflagshipStrategic or Co-development Partner · 9 September 2024National diabetic retinopathy screening program using SELENA+ as the first medical AI adopted in Brunei.
• Sultanate of OmanflagshipStrategic or Co-development Partner · 12 December 2023Secured national screening project in Sultanate of Oman for diabetic retinopathy using AI technology.
• Topcon Healthcare SolutionsmajorTechnology or Integration · 11 November 2020Integration partnership to roll out SELENA+ in Harmony RS for 18 Asian countries, enabling deployment through Topcon's ophthalmic device platform.
• Singapore Eye Research Institute (SERI)coreStrategic or Co-development PartnerResearch partnership for ophthalmic AI development and clinical validation. SERI is one of the major eye research institutes in Asia.
• Singapore National Eye Centre (SNEC)coreStrategic or Co-development PartnerClinical partnership for AI deployment and validation; co-founders are affiliated with SNEC. SNEC Ocular Reading Centre uses EyRIS technology.
• NUS School of ComputingcoreStrategic or Co-development PartnerAcademic partnership with NUS Computer Science faculty (Prof Wynne Hsu and Prof Lee Mong Li) who are co-inventors of SELENA+.
• Singapore Optometric AssociationminorGTM or Marketing PartnerPartnership to expand AI eye screening access through optometry channels in Singapore.
• Diabetes SingaporeminorGTM or Marketing PartnerPartnership to promote diabetic eye screening awareness and services among diabetes patients in Singapore.
• I-Cognitio SciencesminorStrategic or Co-development PartnerStrategic alliance announced August 2024 to explore AI applications in Alzheimer's detection.
• Advance Innovation (Myanmar)minorChannel Partner/ Reseller/ DistributorRegional partnership for Myanmar market deployment of SELENA+ AI diabetic retinopathy screening.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Digital Diagnostics (IDx): Digital Diagnostics is the maker of IDx-DR, an FDA-cleared autonomous AI system for diabetic retinopathy screening. It is a direct peer to EyRIS's SELENA+, competing for the same national screening tenders, hospital deployments, and primary care integration contracts globally.
• Eyenuk: Eyenuk develops the EyeArt AI system for automated diabetic retinopathy screening, with multiple FDA clearances and broad US/EU deployments. It directly competes with SELENA+ in population-screening RFPs and hospital eye-care deployments, and is among EyRIS's closest commercial rivals.
• AEYE Health: AEYE Health produces AI-based retinal screening for diabetic retinopathy with FDA clearance and a portable handheld camera workflow. It competes with EyRIS in primary-care and pharmacy-based screening channels, especially in the US market EyRIS has begun to enter.
• Remidio Innovative Solutions: Remidio combines AI-based retinal screening (including for DR) with portable fundus cameras, targeting emerging markets and community screening. It is comparable to EyRIS on technology, customer base (hospitals and population screening), and geographic focus on Asia/Middle East/Africa.
• MediWhale: Mediwhale develops Reti-CVD and DR-screen AI from retinal images, with regulatory clearances in Korea and expansion into Asia and the Middle East. Comparable to EyRIS as an AI retinal diagnostic company targeting national screening programs and cardiovascular risk assessment from fundus images.

Emerging players

• Optomed: Optomed is a handheld fundus camera manufacturer with integrated AI screening partnerships, including EyRIS. Comparable as a peer because Optomed ships AI retinal screening solutions alongside its hardware, overlapping with EyRIS in primary-care screening workflows.
• I-Cognitio Sciences: I-Cognitio Sciences is an EyRIS strategic alliance partner exploring AI applications in Alzheimer's detection. Comparable as an emerging healthcare AI player expanding beyond ophthalmology into neurodegenerative diagnostics, with overlapping research collaborations with Singapore institutions.
• VUNO: VUNO is a South Korean medical AI company with ophthalmology products (including DR screening) and broader diagnostic AI. It is an EyRIS technology-integration partner and a comparable AI healthcare player competing for hospital and ministry contracts across Asia.
• Topcon Healthcare: Topcon is both an EyRIS partner (Harmony RS integration for 18 Asian countries) and a broader retinal imaging device manufacturer whose own AI strategy overlaps with EyRIS's. Comparable because the partnership signals platform-level competition as well as cooperation in distributing retinal AI.

Broad incumbents

• Google Health (Verily / Google DeepMind): Google's health AI groups (including Verily and DeepMind ophthalmology work) have published landmark retinal AI research and entered screening pilots in India and Thailand. It is a broad incumbent whose entry into national DR screening programs could pressure EyRIS in winning future RFPs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eyris-io

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EyRis